Muscle Exosomes

Overview

Parent Cell: Akira Skeletal Muscle Stem Cells (MuSCs) differentiated from UCT-WJ-MSCs | Muscle-regenerative and anti-atrophic growth factors and miRNAs for muscle repair and regeneration

Related: Exosomes Overview • Skeletal Muscle Cells

FOR RESEARCH USE AND INTERNATIONAL USE ONLY

What Are Exosomes?

Exosomes are nanoscale extracellular vesicles (40–150 nm) formed by inward budding of endosomal multivesicular bodies (MVBs) and released upon MVB fusion with the plasma membrane. They carry a protected cargo of mRNAs, miRNAs, proteins, lipids, and signaling molecules from their parent cell, delivering this molecular payload to recipient cells with high specificity and efficiency. Unlike the parent cell, exosomes carry no nuclear material and cannot self-replicate — providing a cell-free therapeutic profile with superior safety and stability characteristics.

The Akira Muscle Exosome Matrix is derived from skeletal muscle stem cells (MuSCs, also known as satellite cells) produced by directed differentiation of UCT-WJ-MSCs under myogenic induction conditions. These cells express the canonical satellite cell marker Pax7 and the myogenic regulatory factors MyoD and Myogenin, confirming their skeletal muscle progenitor identity. The resulting exosome preparation is enriched with the molecular signals of muscle regeneration, hypertrophy, and anti-atrophy.

Muscle-derived exosomes are an emerging area of research interest due to their role as exercise-induced myokine carriers and their potential in treating muscle wasting conditions (sarcopenia, cachexia, muscular dystrophy). The miRNA cargo of this preparation — miR-206, miR-1, miR-133a/b — collectively regulate satellite cell activation, myoblast proliferation, muscle fiber hypertrophy, and anti-fibrotic remodeling. Follistatin in the secretome is a potent myostatin antagonist, providing direct anti-atrophy signaling.^[1]

Mechanism of Action

Satellite Cell Activation & Myogenesis: HGF activates quiescent satellite cells through the c-Met receptor, initiating the myogenic program. miR-206 — the defining muscle miRNA — promotes MyoD expression and myoblast differentiation while suppressing PAX7 to drive terminal differentiation. miR-1 reinforces myogenic commitment by suppressing HDAC4. FGF-2 drives satellite cell proliferation to expand the myoblast pool prior to fusion and hypertrophic remodeling. Satellite cell dysfunction is itself a recognized contributor to impaired regeneration across neuromuscular disorders, underscoring the rationale for directly re-activating this population.^[2]

Muscle Fiber Hypertrophy & IGF-1 Signaling: IGF-1 activates PI3K/Akt/mTOR in myofibers, the primary pathway driving protein synthesis and muscle hypertrophy. miR-486 suppresses PTEN, amplifying PI3K/Akt signaling.^[3] This combination of direct IGF-1 cargo and PTEN-suppressing miRNA creates a potent pro-hypertrophic environment in recipient muscle tissue, relevant to sarcopenia, atrophy, and muscle-wasting research contexts.

Myostatin Antagonism & Anti-Atrophy: Follistatin is the primary endogenous antagonist of myostatin (GDF-8), the key negative regulator of muscle mass. The Muscle Exosome secretome delivers follistatin at concentrations sufficient to substantially reduce myostatin signaling in recipient tissues. miR-133a/b additionally suppress myostatin-associated downstream targets — consistent with myostatin-null models showing elevated miR-133a/b expression.^[4] This dual anti-myostatin mechanism is directly relevant to cachexia, sarcopenia, and muscular dystrophy research.^[5]

Muscle Fibrosis Reduction: TGF-β signaling in injured muscle drives fibro/adipogenic progenitor (FAP) activation and replacement of functional muscle with fibrotic connective tissue. miR-133a suppresses connective tissue growth factor (CTGF) and TGF-β pathway components — demonstrated directly in pulmonary myofibroblasts^[6] and proposed to extend to fibro/adipogenic progenitors in skeletal muscle — reducing fibrotic replacement of damaged muscle. This is particularly relevant in chronic muscle disease (Duchenne MD) and recurrent injury contexts.

Key Molecular Cargo

Potential Applications

• Sarcopenia Research: IGF-1/follistatin anti-atrophy cargo; satellite cell activation via HGF (published MSC-exosome atrophy models also implicate other pathways, e.g. estrogen signaling^[7]), consistent with the broader pathophysiology of primary sarcopenia.^[8]
• Muscular Dystrophy: Myogenin/MyoD-associated cargo supports residual satellite cell myogenesis; miR-133a anti-fibrotic (published dystrophic-muscle exosome studies also demonstrate benefit via membrane-integrity stabilization), consistent with intrinsic muscle stem cell dysfunction documented in the mdx dystrophy mouse model.^[9]
• Cancer Cachexia: Follistatin myostatin antagonism; IGF-1/mTOR anabolic signaling.
• Post-Traumatic Muscle Injury: HGF satellite cell activation; miR-206 myogenic program induction; VEGF angiogenesis, an approach with precedent in adipose-MSC-exosome amelioration of skeletal muscle injury in mouse models.^[10]
• Sports Medicine Research: Satellite cell pool expansion via FGF-2/HGF; muscle fiber hypertrophy via IGF-1.
• Denervation Atrophy: Maintenance of muscle fiber size via IGF-1/follistatin.
• Inflammatory Myopathy: Anti-inflammatory secretome components reduce immune-mediated muscle destruction, extrapolated from whole-MSC transplantation improving creatine kinase levels, muscle strength, and clinical status in drug-resistant polymyositis/dermatomyositis patients.^[11]
• Metabolic Muscle Disease: Mitochondrial biogenesis and AMPK pathway engagement, shown for hucMSC exosomes generally in a sarcopenia mouse model — not yet demonstrated for this differentiated version specifically.^[12]

These are experimental use cases, provided as a scientific reference for researchers. Except where noted, they did not use Akira Biotech materials, and results may not be reproducible with ours. Akira Biotech supplies laboratory reagents for research use only. Our products are NOT approved by FDA or any regulatory authority and are not for use in or on humans.

Clinical & Preclinical Evidence

Direct clinical trial data specific to this exosome preparation is not yet available; the evidence base is preclinical and mechanistic, and draws on whole-cell trial data from the same skeletal muscle stem cell lineage.